NCT00707304COMPLETEDanonymous

FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

Sponsor

Source record

Agennix

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Non-small Cell Lung Cancer

Indication / condition

AI-normalized

Non Small Cell Lung Cancer

Intervention

Source record

Talactoferrin, Placebo

Source & freshness

Source record

NCT ID

NCT00707304

Original source

ClinicalTrials.gov

Source last updated

Aug 21, 2012

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00707304

Title

FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

Sponsor

Agennix

Status

COMPLETED

Phase

Phase 3

Condition raw

Non Small Cell Lung Cancer

Condition normalized

Non Small Cell Lung Cancer

Modality raw

Non Small Cell Lung Cancer

Modality normalized

small molecule

Target raw

Non-small Cell Lung Cancer

Target normalized

Non-small Cell Lung Cancer

Interventions

Talactoferrin, Placebo

Public preview

Source record

The FORTIS-M trial evaluated the safety and efficacy of talactoferrin in patients with non-small cell lung cancer (NSCLC) who had failed two or more prior treatment regimens. The study aimed to determine if talactoferrin could improve overall survival when combined with best supportive care.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00707304

Status

COMPLETED

Phase

Phase 3

Sponsor

Agennix

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 21, 2012

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00707304

Indication

Non Small Cell Lung Cancer

Modality

small molecule

Target

Non-small Cell Lung Cancer

Intervention

Talactoferrin, Placebo

Source record